Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Clasificación en acciones #4543
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Precio por acción
$27.18
Última sincronización: 2026-07-31
Capitalización bursátil
$3.38B
Cambio (1 día)
-1.41%
Cambio (1 año)
202.34%
País
US
Comercio Tango Therapeutics, Inc. (TNGX)

Categoría

Healthcare
Ratio P/S de Tango Therapeutics, Inc. (TNGX)
Ratio P/S al October 2026 TTM: 67.14
Según los informes financieros más recientes y el precio de las acciones de Tango Therapeutics, Inc., el ratio P/S actual (TTM) es 67.14. Al final de 2023, el ratio P/S era 25.63.
Historial del ratio P/S de Tango Therapeutics, Inc. desde 2019 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 67.14 737.15%
2024 8.02 -68.70%
2023 25.63 0.08%
2022 25.61 39.62%
2021 18.34 -61.56%
2020 47.71 1,179.46%
2019 3.73 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.02 -85.07%
US
40.55 -39.60%
US
3.96 -94.10%
AU
- -
CH
10.15 -84.89%
NL